PATENT CLAIM ANALYSIS

Application Number: 16050102
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["514", "004800"]

Abstract:
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

Claim (Index 16):
An amylin analogue according to  claim 1  wherein Z is an amino acid sequence selected from the group consisting of: (SEQ\u2003ID\u2003NO:\u20035) RD()GTAT-Dap()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u20036) RD()GTAT-Dab()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u20037) RD()GTAT-Orn()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u20038) RD()GTAT-Orn()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-PSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u20039) RD()GTAT-Orn()-ATERLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200310) RD()GTAT-Orn()-ATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNTP   (SEQ\u2003ID\u2003NO:\u200311) RD()GTAT-Orn()-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200312) RD()GTAT-Orn()-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-PSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200313) RD()GTAT-Orn()-ATERLARFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200314) ED()GTATK()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200315) RD()GEATK()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200316) RD()GTLTK()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200317) RD()GTASK()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200318) RD()GTATK()ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-PSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200319) RD()GTATK()ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200320) RD()GTATK()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-PSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200321) RD()GTATK()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200322) RD()GTAT-hLys()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200323) RD()GTAT-Orn()-ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200324) RD()GTAT-Orn()-ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-PSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200325) RD()GTAT-Orn()-ATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSST-Hyp   (SEQ\u2003ID\u2003NO:\u200326) RD()GTAT-Orn()-ATERLA-Aad-FLQRTTF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200327) RD()GTAT-Orn()-ATERLA-Aad-FLQRTTF-Gly(Me)-A-Ile(Me)-PSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200328) RD()GTAT-Orn()-ATERLA-Aad-FLQRATF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200329) RD()GTAT-Orn()-ATERLA-Aad-FLQRAAF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200330) RD()GTAT-Orn()-ATERLA-Aad-FLQRGTF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200331) RD()QTAT-Orn()-ATERLA-Aad-FLQRGTF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200332) RD()PTATK()ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200333) ED()GTATK()ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-PSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200334) RD()GTATK()ATERLA-Aad-FLQRAAF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200335) RD()GTATK()ATERLA-Aad-FLQRGGF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200336) RD()GTATK()ATERLA-Aad-FLQRANF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200337) RD()GTATK()ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-PSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200338) RD()GTATK()ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200339) RD()GTATK()ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTETGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200340) ED()GTATK()ATERLA-Aad-FLQRSSFGly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200341) RD()GTATK()ATERLA-Aad-FLQRTTF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200342) KD()GTATK()ATQRLA-Aad-FLQRSSF-Gly(Me)-AIle(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200343) RD()GTATK()ATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200344) RD()GTATK()ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200345) RD()GTATK()ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTETGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200346) KD()GTATK()ATQRLANFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200347) KD()GTATK()ATQRLANFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTETGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200348) R-Dap()-GTATD()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200349) R-Dab()-GTATD()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200350) R-Orn()-GTATD()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200351) R-Dap()-GTAT-Aad()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200352) R-Dab()-GTATE()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200353) R-Aad()-GTAT-Dap()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp   (SEQ\u2003ID\u2003NO:\u200354) RE()GTAT-Dab()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 95.0
- Lexical Diversity: 1.4898
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15698743', '14398260', '11278014', '14800627', '15442229']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8129257022392067
- 35 USC 102 Novelty (BERT): 0.7371105838610083
- Combined Prediction Score: 0.8053441904013868
- Mean Citation Score: 487.11570200000006
- Max Citation Score: 847.1067
- Similarity Product: 810.3963039242328

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test